Sevelamer Hydrochloride: Uses, Dosage, Side Effects & Brands | MedexInfo

Sevelamer Hydrochloride

Generic NameSevelamer Hydrochloride

Therapeutic ClassPhosphate Binder

Common Strength400 mg, 800 mg tablets; 2.4 g powder for oral suspension

Max / 24hIndividualized; titrate based on serum phosphate

PregnancyUse if clearly needed

Indications ▼

Hyperphosphatemia in Chronic Kidney Disease (CKD): For adult and pediatric patients on hemodialysis or peritoneal dialysis with elevated serum phosphate. High phosphate is linked to secondary hyperparathyroidism, bone disease, and cardiovascular calcification.

Prevention of Vascular Calcification: Reduces phosphate load without increasing calcium or aluminum, lowering risk of arterial and soft tissue calcification.

Adjunct to Diet: Used with a phosphate-restricted diet to maintain target serum phosphate (usually 3.5–5.5 mg/dL in dialysis patients).

Pediatric Patients: Approved for children ≥6 years on dialysis; dosing must be individualized and monitored carefully.

Off-label / Non-dialysis CKD: Occasionally used in patients with persistent hyperphosphatemia despite dietary restrictions; only under physician supervision.

Mechanism & Pharmacokinetics ▼

Mechanism: Sevelamer Hydrochloride is a non-absorbed polymer that binds dietary phosphate in the gut. This prevents phosphate absorption and lowers serum phosphate levels without adding calcium or aluminum.

Pharmacokinetics: Not systemically absorbed; acts locally in the gastrointestinal tract. Excreted unchanged in feces. Effect is dose-dependent and correlates with dietary phosphate intake.

Dosage & Administration ▼

Indication	Dose	Frequency
Hyperphosphatemia in adults	800–1600 mg per meal (initial)	3 times daily with meals
Hyperphosphatemia in pediatric patients (≥6 yrs)	Initial: 400–800 mg per meal	3 times daily; adjust based on serum phosphate

Note: Dose titration should occur every 2–4 weeks to reach target serum phosphate. Powder can be mixed with water for easier administration. Avoid simultaneous administration with medications that require absorption monitoring.

Side Effects ▼

Constipation, diarrhea, nausea

Abdominal pain, bloating, flatulence

Rare: intestinal obstruction, fecal impaction

May reduce absorption of fat-soluble vitamins (A, D, E, K)

Contraindications ▼

Hypersensitivity to Sevelamer Hydrochloride

Hypophosphatemia

Bowel obstruction, swallowing disorders, or severe gastrointestinal motility disorders

Drug Interaction ▼

May reduce absorption of certain drugs (ciprofloxacin, levothyroxine, mycophenolate, fat-soluble vitamins). Administer these drugs at least 1 hour before or 3 hours after Sevelamer.

Pregnancy & Lactation ▼

Use only if clearly needed; no well-controlled studies in pregnant women.

Breastfeeding: Use only if benefits outweigh risks.

Clinical / Research Summary ▼

Clinical Role: First-line non-calcium phosphate binder for CKD patients on dialysis.

Advantage: Lowers phosphate without increasing calcium load; reduces vascular calcification risk.

Limitation: Gastrointestinal side effects; careful monitoring of serum phosphate, calcium, and vitamins needed.

Monitoring: Serum phosphate, calcium, bicarbonate, vitamin D, bowel habits, and adherence to diet.

Patient Counseling Points ▼

Take with meals to maximize phosphate binding.

Do not crush or chew tablets; mix powder with water if needed.

Report constipation, severe abdominal pain, or signs of bowel obstruction immediately.